Treatment with statins may be considered in ESRD patients for primary prevention of cardiovascular disease.
作者信息
Manca-di-Villahermosa Simone, Taccone-Gallucci Massimo, Maccarrone Mauro
机构信息
Department of Internal Medicine, Tor Vergata University, Rome, Italy, and Nephrology and Dialysis Unit, Tor Vergata University Hospital, Rome, Italy.
Department of Internal Medicine, Tor Vergata University, Rome, Italy, and Nephrology and Dialysis Unit, Tor Vergata University Hospital, Rome, Italy.
出版信息
Kidney Int. 2009 Jun;75(12):1354-1355. doi: 10.1038/ki.2009.107.
PMID:19483750
Abstract
摘要
相似文献
1
Treatment with statins may be considered in ESRD patients for primary prevention of cardiovascular disease.
Kidney Int. 2009 Jun;75(12):1354-1355. doi: 10.1038/ki.2009.107.
2
Should statins be prescribed for primary prevention of cardiovascular disease in patients with chronic kidney disease?
BMJ. 2009 Aug 20;339:b2949. doi: 10.1136/bmj.b2949.
3
[Statins in chronic renal disease].
Arq Bras Cardiol. 2005 Oct;85 Suppl 5:45-9. Epub 2006 Jan 2.
4
Nephroprotective and clinical potential of statins in dialyzed patients.
Expert Opin Ther Targets. 2009 May;13(5):541-50. doi: 10.1517/14728220902882130.
5
Statins for end-stage kidney disease treated with dialysis.
Nephrology (Carlton). 2015 Apr;20(4):302-3. doi: 10.1111/nep.12435.
6
Statins do not improve cardiovascular outcomes for dialysis patients.
Evid Based Med. 2014 Jun;19(3):89. doi: 10.1136/eb-2013-101606. Epub 2013 Dec 12.
7
HMG-CoA reductase inhibitors and the kidney.
Curr Hypertens Rep. 2005 Oct;7(5):337-42. doi: 10.1007/s11906-005-0066-4.
8
Rosuvastatin in patients undergoing hemodialysis.
N Engl J Med. 2009 Jul 2;361(1):93-4; author reply 94-5.
9
Statins in the prevention of cardiovascular events in patients with renal failure.
Cardiovasc Hematol Disord Drug Targets. 2007 Mar;7(1):7-13. doi: 10.2174/187152907780059119.
10
Rosuvastatin in patients undergoing hemodialysis.
N Engl J Med. 2009 Jul 2;361(1):93; author reply 94-5.
Zotero 插件